Vigil immunotherapy tolerated well for recurrent ovarian CA Tx
(HealthDay)—Vigil immunotherapy shows good tolerability for recurrent ovarian cancer patients, and PARP 7, a poly(ADP-ribose) polymerase protein, may play a significant role in survival for ovarian cancer, according to ...
Mar 27, 2018
0
4